Communiqués Sharp Therapeutics Corp.

Actions

SHRX

CA8200092077

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. Autres places de cotation 20:39:09 30/06/2026			Varia. 5j.	Varia. 1 janv.
0,9100 ^CAD	-9,00%		-.--%	-63,60%

29/07	Sharp Therapeutics lève 1,37 million de dollars canadiens via un placement privé sans intermédiaire	MT
28/05	Sharp Therapeutics présente de nouvelles données précliniques appuyant une approche thérapeutique innovante par petites molécules pour la maladie de Niemann-Pick de type C	RE

Communiqués

29/07	Sharp Therapeutics Announces Closing of Non-Brokered Private Placement	NE
21/07	Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders	NE
15/07	Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update	NE
30/06	Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date	NE
28/05	Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C	AQ
18/04	Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting	NE
13/04	Sharp Therapeutics Updates on 901 for Gaucher and GBA1 Parkinson's and Platform Programs	AQ
10/04	Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs	NE
10/04	Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering	NE
02/04	Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering	NE
13/03	Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering	NE
27/02	Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering	NE
02/02	Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes	NE
27/01	Sharp Therapeutics Appoints Co-Founder Of National Gaucher Foundation And Clinical Researcher Robin Ely, M.D., To Advisory Board	AQ
19/12	Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options	NE
26/11	Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update	NE
14/10/25	Canadian Investment Regulatory Organization Trade Resumption - SHRX	AQ
14/10/25	Canadian Investment Regulatory Organization Trading Halt - SHRX	AQ
14/10/25	Sharp Therapeutics Arranges Non-Brokered Private Placement	NE
08/10/25	Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025	AQ
29/08/25	Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB	NE
29/07/25	Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease	NE
21/07/25	Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders	NE
22/05/25	Sharp Therapeutics Corp. Reports First Quarter 2025 Results	NE
13/05/25	Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease	NE